Evidence map›Paper›PMID 32788404›Full record

ArticlemSystems2020

Development of a Counterselectable Transposon To Create Markerless Knockouts from an 18,432-Clone Ordered Mycobacterium bovis Bacillus Calmette-Guérin Mutant Resource.

Katlyn Borgers, Kristof Vandewalle, Annelies Van Hecke, Gitte Michielsen, Evelyn Plets, Loes van Schie, Sandrine Vanmarcke, Laurent Schindfessel, Nele Festjens, Nico Callewaert

Open access · goldAbstract read
In one paragraph

Article in mSystems, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Katlyn BorgersCenter for Medical Biotechnology, VIB-Ghent University, Ghent, Belgium.ORCID https://orcid.org/0000-0002-9289-1503
Kristof VandewalleCenter for Medical Biotechnology, VIB-Ghent University, Ghent, Belgium.
Annelies Van HeckeCenter for Medical Biotechnology, VIB-Ghent University, Ghent, Belgium.
Gitte MichielsenCenter for Medical Biotechnology, VIB-Ghent University, Ghent, Belgium.
Evelyn PletsCenter for Medical Biotechnology, VIB-Ghent University, Ghent, Belgium.
Loes van SchieCenter for Medical Biotechnology, VIB-Ghent University, Ghent, Belgium.
Sandrine VanmarckeCenter for Medical Biotechnology, VIB-Ghent University, Ghent, Belgium.
Laurent SchindfesselDepartment of Civil Engineering, Ghent University, Ghent, Belgium.
Nele FestjensCenter for Medical Biotechnology, VIB-Ghent University, Ghent, Belgium.
Nico CallewaertCenter for Medical Biotechnology, VIB-Ghent University, Ghent, Belgium Nico.Callewaert@vib-ugent.be.ORCID https://orcid.org/0000-0003-2069-6917
Ghent University · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutant resources are essential to improve our understanding of the biology of slow-growing mycobacteria, which include the causative agents of tuberculosis in various species, including humans. The generation of deletion mutants in slow-growing mycobacteria in a gene-by-gene approach in order to make genome-wide ordered mutant resources is still a laborious and costly approach, despite the recent development of improved methods. On the other hand, transposon mutagenesis in combination with Cartesian pooling-coordinate sequencing (CP-CSeq) allows the creation of large archived

Indexed as

characterized transposon libraryMycobacterium tuberculosis complexoptimized Himar1 transposontransposon mutagenesisunmarked mutants

Identifiers

PMID32788404
PMCPMC7426150
OpenAlexW3048931526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.